Прати
Dusan Ruzic
Dusan Ruzic
Верификована је имејл адреса на pharmacy.bg.ac.rs
Наслов
Навело
Навело
Година
In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs
Z Gagic, D Ruzic, N Djokovic, T Djikic, K Nikolic
Frontiers in chemistry 7, 873, 2020
932020
Modulating protein–protein interactions with visible‐light‐responsive peptide backbone photoswitches
L Albert, A Peñalver, N Djokovic, L Werel, M Hoffarth, D Ruzic, J Xu, ...
ChemBioChem 20 (11), 1417-1429, 2019
422019
Targeting histone deacetylases: opportunities for cancer treatment and chemoprevention
D Ruzic, N Djoković, T Srdić-Rajić, C Echeverria, K Nikolic, JF Santibanez
Pharmaceutics 14 (1), 209, 2022
322022
Quantitative structure-retention relationship of selected imidazoline derivatives on α1-acid glycoprotein column
S Filipic, D Ruzic, J Vucicevic, K Nikolic, D Agbaba
Journal of Pharmaceutical and Biomedical Analysis 127, 101-111, 2016
252016
Combined Ligand and Fragment‐based Drug Design of Selective Histone Deacetylase–6 Inhibitors
D Ruzic, M Petkovic, D Agbaba, A Ganesan, K Nikolic
Molecular Informatics 38 (5), 1800083, 2019
242019
Bistable photoswitch allows in vivo control of hematopoiesis
L Albert, J Nagpal, W Steinchen, L Zhang, L Werel, N Djokovic, D Ruzic, ...
ACS central science 8 (1), 57-66, 2021
202021
In silico identification of novel 5-HT2A antagonists supported with ligand- and target-based drug design methodologies
M Radan, D Ruzic, M Antonijevic, T Djikic, K Nikolic
Journal of Biomolecular Structure and Dynamics 39 (5), 1819-1837, 2021
142021
Discovery of 1-benzhydryl-piperazine-based HDAC inhibitors with anti-breast cancer activity: synthesis, molecular modeling, in vitro and in vivo biological evaluation
D Ruzic, B Ellinger, N Djokovic, JF Santibanez, S Gul, M Beljkas, A Djuric, ...
Pharmaceutics 14 (12), 2600, 2022
122022
Dual LSD1 and HDAC6 inhibition induces doxorubicin sensitivity in acute myeloid leukemia cells
I Bulut, A Lee, B Cevatemre, D Ruzic, R Belle, A Kawamura, S Gul, ...
Cancers 14 (23), 6014, 2022
112022
Fragment-based drug design of selective HDAC6 inhibitors
D Ruzic, N Djokovic, K Nikolic
Protein-Ligand Interactions and Drug Design, 155-170, 2021
112021
Structure-based design of selective histone deacetylase 6 zinc binding groups
LA Alves Avelar, D Ruzic, N Djokovic, T Kurz, K Nikolic
Journal of Biomolecular Structure and Dynamics 38 (11), 3166-3177, 2020
112020
Anticancer evaluation of the selected tetrahydropyrimidines: 3D-QSAR, cytotoxic activities, mechanism of action, DNA, and BSA interactions
E Milović, J Petronijević, N Joksimović, M Beljkaš, D Ružić, K Nikolić, ...
Journal of Molecular Structure 1257, 132621, 2022
102022
Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics
N Djokovic, D Ruzic, M Rahnasto-Rilla, T Srdic-Rajic, ...
Journal of Chemical Information and Modeling 62 (10), 2571-2585, 2022
92022
Extending cross metathesis to identify selective HDAC inhibitors: synthesis, biological activities, and modeling
S Bouchet, C Linot, D Ruzic, D Agbaba, B Fouchaq, J Roche, K Nikolic, ...
ACS Medicinal Chemistry Letters 10 (6), 863-868, 2019
92019
An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease
N Djokovic, D Ruzic, T Djikic, S Cvijic, J Ignjatovic, S Ibric, K Baralic, ...
Molecular Informatics 40 (5), 2000187, 2021
82021
Synthesis and biological activity of a cytostatic inhibitor of MLLr leukemia targeting the DOT1L protein
C Bon, Y Si, M Pernak, M Barbachowska, E Levi-Acobas, V Cadet Daniel, ...
Molecules 26 (17), 5300, 2021
62021
Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinoma
N Djokovic, A Djuric, D Ruzic, T Srdic-Rajic, K Nikolic
Pharmaceuticals 16 (2), 294, 2023
42023
Medicinal chemistry of histone deacetylase inhibitors
ZV D. Ruzic, N. Djokovic, K. Nikolic
Archives of Pharmacy, https://aseestant.ceon.rs/index.php/arhf, 2021
3*2021
Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
M Beljkas, A Ilic, A Cebzan, B Radovic, N Djokovic, D Ruzic, K Nikolic, ...
Pharmaceutics 15 (11), 2581, 2023
22023
Discovery of 1-benzhydryl piperazine-based HDAC inhibitors with anti-cancer and anti-metastatic properties against human breast cancer: synthesis, molecular modeling, in vitro …
D Ruzic, M Petkovic, N Djokovic, J Santibanez, B Ellinger, M Beljkas, ...
12022
Систем тренутно не може да изврши ову радњу. Пробајте поново касније.
Чланци 1–20